Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compli... Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. Show more
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins...
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -2.85714285714 | 2.45 | 2.56 | 2.22 | 59843 | 2.42405489 | CS |
4 | 0.18 | 8.18181818182 | 2.2 | 2.79 | 2.07 | 275446 | 2.5975634 | CS |
12 | 0.62 | 35.2272727273 | 1.76 | 2.79 | 1.5373 | 152116 | 2.25293889 | CS |
26 | 0.68 | 40 | 1.7 | 2.79 | 1.41 | 85624 | 2.15216195 | CS |
52 | 1.538 | 182.660332542 | 0.842 | 3.35 | 0.6801 | 125067 | 2.06427159 | CS |
156 | 0.07 | 3.0303030303 | 2.31 | 3.35 | 0.4722 | 105957 | 1.52454816 | CS |
260 | -0.82 | -25.625 | 3.2 | 10.16 | 0.4722 | 816118 | 4.77515871 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales